MONTREAL, March 8, 2022 /CNW Telbec/ - Lumiera Health
Inc. (TSXV: NHP) (the "Company" or
"Lumiera "), a company specializing in the development
and commercialization of evidence-based botanical products, is
pleased to announce two significant milestones on the path to
Awaye™ sales in the United States.
As previously announced, Pain Level LLC will be representing the
company's Awaye™ pain relief product in the Northeastern US market.
The definitive agreement with Pain Level LLC has been signed, and
the launch plans are moving forward.
Lumiera is also pleased to announce that the U.S. Food &
Drug Administration (FDA) has published final registration of the
Company's National Drug Code (NDC) number (82531-001) for its
Awaye™ Pain Relief Cream. An NDC is the FDA's unique identifier for
drugs and allows Awaye™ to be sold as an OTC drug anywhere in the
US. The NDC number has also enabled the Company to complete the US
version of the product packaging which enables production for US
inventory to begin.
"Awaye™ has received very positive feedback from consumers; it
is helping people manage their pain naturally, and we are very
excited to expand distribution in the Northeastern US market to
help people manage their pain and to accelerate our growth. The
finalization of the agreement with Pain Level LLC and the NDC are
two significant milestones; we can now move forward with
production, inventory builds and sales execution. I look
forward sharing additional milestones as we execute our plans."
says Carlos Ponce, CEO of
Lumiera.
About Awaye™
Awaye™ provides a new generation of relief from acute and
chronic pain by exploiting the CB2 receptors of the endocannabinoid
system, the body's built in pain and inflammation defense system.
Awaye™ is a unique Health Canada approved topical cream that
provides relief from pain through complimentary mechanisms of
action not found in any other product currently available on the
market.
For more information about Awaye™ products, visit
www.awaye.ca
About Pain Level LLC
Pain Level LLC is led by Jerry
Safran. Mr. Safran has 20+ years' experience building
retail brands in the grocery & supplements sector, and has
developed deep relationships with major super-market chains, big
box retailers and pharmacies. Jerry is joined by Daniel Katcher, a proven leader for 25 years in
commercial sales. Deborah Kogan
Eilender, a veteran brand-builder in the healthcare industry
and former marketing director for a global fortune 100
pharmaceutical company, provides the marketing expertise for
Pain Level LLC.
About Lumiera Health
Lumiera specializes in the development and commercialization of
consumer products for the natural health industry. The Company
sells herbal tonics and natural supplements through its Holizen
Laboratories division, with a diverse portfolio including a line of
innovative sleep aids. The Company is also commercializing a unique
topical product line acting on the endocannabinoid system, without
the use of cannabis, that provides an innovative solution for
chronic pain and inflammation. A pioneer in the natural health
innovation space, the Lumiera brand is rooted in the core values of
science, nature and compassion. Our goal is to make people's
lives better by developing natural health and wellness products
that are effective, safe and trustworthy.
For more information visit: www.lumiera.ca.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking information
Certain statements contained in this press release constitute
"forward-looking information" as such term is defined in applicable
Canadian securities legislation. The words "may", "would", "could",
"should", "potential", "will", "seek", "intend", "plan",
"anticipate", "believe", "estimate", "expect" and similar
expressions indicate such "forward-looking
information" as they relate to Lumiera. All statements other
than statements of historical fact may be forward-looking
information. Such statements reflect Lumiera' current views and
intentions with respect to future events, and current information
available to Lumiera, and are subject to certain risks,
uncertainties and assumptions. Such risks and uncertainties
include, among others, the risk factors included in Lumiera' annual
management's discussion and analysis for the year
ended November 30, 2020,
which is available under the issuer's SEDAR profile
at www.sedar.com. Material factors or assumptions
were applied in providing forward-looking information. Many factors
could cause the actual results, performance or achievements that
may be expressed or implied by such forward-looking information to
vary from those described herein should one or more of these risks
or uncertainties materialize. Should any factor affect Lumiera in
an unexpected manner, or should assumptions underlying the
forward-looking information prove incorrect, the actual results or
events may differ materially from the results or events predicted.
Any such forward-looking information is expressly qualified in its
entirety by this cautionary statement. Moreover, Lumiera does not
assume responsibility for the accuracy or completeness of such
forward-looking information. The forward-looking information
included in this press release is made as of the date of this press
release and Lumiera undertakes no obligation to publicly update or
revise any forward-looking information, other than as required by
applicable law.
Related Links: www.lumiera.ca
SOURCE Lumiera Health Inc.